Telix Pharmaceuticals Limited (TLX)

Market Cap	2.70B
Revenue (ttm)	664.23M
Net Income (ttm)	10.84M
Shares Out	338.40M
EPS (ttm)	0.04
PE Ratio	249.18
Forward PE	224.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,730
Open	8.05
Previous Close	8.10
Day's Range	8.02 - 8.14
52-Week Range	7.72 - 30.36
Beta	1.22
Analysts	Strong Buy
Price Target	21.00 (+161.52%)
Earnings Date	Jan 15, 2026

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: NASDAQ
• Ticker Symbol: TLX
• Website: https://telixpharma.com

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.

Analyst Summary

According to 4 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 161.52% from the latest price.

Price Target

$21.0

(161.52% upside)

Analyst Consensus: Strong Buy